Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by JPMorgan Chase & Co. from $455.00 to $457.00 in a research note issued to investors on Wednesday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 22.08% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. BTIG Research reiterated a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, November 27th. Citigroup downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Piper Jaffray Companies reiterated a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, SunTrust Banks reiterated a “hold” rating and set a $435.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $471.19.
Regeneron Pharmaceuticals (REGN) traded down $17.48 during trading hours on Wednesday, reaching $374.36. 1,414,838 shares of the company’s stock traded hands, compared to its average volume of 681,361. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals has a 52-week low of $340.96 and a 52-week high of $543.55. The stock has a market cap of $38,430.00, a P/E ratio of 34.00, a P/E/G ratio of 1.50 and a beta of 1.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.13 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals will post 13.55 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $130,000. Steward Partners Investment Advisory LLC boosted its position in shares of Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 307 shares during the last quarter. Vident Investment Advisory LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $200,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $206,000. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $217,000. 66.82% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.